• Explore /
  • Poster
  • / Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Abstract Poster

Authors

null

Salah-Eddin Al-Batran

Institute of Clinical Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany

Salah-Eddin Al-Batran , Claudia Pauligk , Ralf Hofheinz , Sylvie Lorenzen , Andreas Wicki , Alexander Rheinhard Siebenhuener , Michael Schenk , Manfred Welslau , Vera Heuer , Eray Goekkurt , Harald Schmalenberg , Peter C. Thuss-Patience , Lisa Waberer , Jonathan Talbot , Thorsten Oliver Goetze , Nils Homann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03421288

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4142)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4142

Abstract #

TPS4142

Poster Bd #

246b

Abstract Disclosures

Similar Posters

First Author: Salah-Eddin Al-Batran

First Author: Hongli Li

First Author: Ralf Hofheinz

First Author: Ralf Hofheinz